Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
HONG KONG, Aug 2, 2025 - (ACN Newswire) - Everest Medicines (HKEX: 1952.HK) today announced a strategic equity investment in I-Mab